Study S001278

Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00781937
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 422
Start: 2008-10-30
Primary completion: 2010-09-01
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE

Registered primary outcomes

Mean Percentage Change in Fasting Body Weight From Baseline [Week 0, week 56]
Percentage of Subjects Who Maintained Their run-in Fasting Weight Loss From Week 0 [Week 0, week 56]
Percentage of Subjects Who Lost More Than or Equal to 5% of Fasting Body Weight From Week 0 [Week 0, week 56]

Linked records (8)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013170	Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Davies MJ, Diabetes, obesity & metabolism	2018	Systematic review	PMID 28950422 DOI	registry reference RESULT:28950422
R0022210	Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. O'Neil PM, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28386912 DOI	registry reference RESULT:28386912
R0025365	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Steinberg WM, Diabetes care	2017	Randomized trial	PMID 28473337 DOI	registry reference RESULT:28473337
R0025976	Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects. Bays H, Current medical research and opinion	2017	Randomized trial	PMID 27817208 DOI	registry reference RESULT:27817208
R0043842	Early responders to liraglutide 3.0 mg as adjunct to diet and exercise from the SCALE Maintenance trial wharton sean	2017	Randomized trial	DOI	cites ClinicalTrials.gov:NCT00781937
R0026243	EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS. O'Neil PM, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2016	Randomized trial	PMID 27482610 DOI	registry reference RESULT:27482610
R0027588	Missing data in clinical trials for weight management. McEvoy BW, Journal of biopharmaceutical statistics	2016	Narrative review	PMID 26418188 DOI	registry reference RESULT:26418188
R0023762	Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Wadden TA, International journal of obesity (2005)	2013	Randomized trial	PMID 23812094 DOI	cites ClinicalTrials.gov:NCT00781937; registry reference RESULT:23812094